Patents by Inventor Julien SOURIMANT

Julien SOURIMANT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BICYCLIC FUSED PYRAZOLE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY INFECTIONS INCLUDING RSV
    Publication number: 20240352013
    Abstract: Disclosed herein are compounds and compositions for inhibiting, treating or preventing respiratory infections, illnesses, diseases, and other respiratory conditions such as those caused by viruses including RSV, coronavirus, and related members of the pneumovirus and paramyxovirus families such as human metapneumovirus, mumps virus, human parainfluenzaviruses, and Nipah and hendra virus. Methods of inhibition, treatment or prevention of infections and diseases caused by these viruses are also provided.
    Type: Application
    Filed: July 29, 2022
    Publication date: October 24, 2024
    Inventors: Richard Plemper, Julien Sourimant
  • Inhibitors of RSV replication and applications thereof
    Patent number: 12016863
    Abstract: Disclosed herein are compounds having antiviral activity, and, in particular, an inhibitory activity on the replication of Respiratory Syncytial Virus (RSV). Druggable target sites, including Px, in the RSV N protein are disclosed, as well as compounds targeting Px. The compounds can be used to treat patients with RSV infection.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: June 25, 2024
    Assignees: Georgia State University Research Foundation, Inc., Emory University
    Inventors: Richard Plemper, Julien Sourimant, Edgars Jecs, Dennis Liotta, Stephen Pelly, Robert Wilson, Zackery Will Dentmon
  • INHIBITORS OF RSV REPLICATION AND APPLICATIONS THEREOF
    Publication number: 20210244740
    Abstract: Disclosed herein are compounds having antiviral activity, and, in particular, an inhibitory activity on the replication of Respiratory Syncytial Virus (RSV). Druggable target sites, including Px, in the RSV N protein are disclosed, as well as compounds targeting Px. The compounds can be used to treat patients with RSV infection.
    Type: Application
    Filed: May 3, 2019
    Publication date: August 12, 2021
    Inventors: Richard PLEMPER, Julien SOURIMANT, Edgars JECS, Dennis LIOTTA, Stephen PELLY, Robert WILSON, Zackery Will DENTMON